魚のワクチンの世界市場

魚のワクチンの世界市場は2030年までに5億7,750万米ドルに達する見込み

2024年に3億6,390万米ドルと推定される魚のワクチンの世界市場は、2030年には5億7,750万米ドルに達し、分析期間2024-2030年のCAGRは8.0%で成長すると予測されます。本レポートで分析したセグメントの1つであるキルドワクチンは、CAGR 10.6%を記録し、分析期間終了時には1億8,300万米ドルに達すると予測されます。不活化ワクチン分野の成長率は、分析期間中CAGR 7.6%と推定されます。

米国市場は9,910万米ドルと推定、中国はCAGR12.9%で成長予測

米国の魚のワクチン市場は、2024年に9,910万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを12.9%として、2030年までに1億2,650万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.8%と7.8%と予測されています。欧州では、ドイツがCAGR 5.3%で成長すると予測されています。

世界の魚のワクチン市場- 主要動向と促進要因のまとめ

なぜ魚のワクチンは持続可能な水産養殖の成長に不可欠になりつつあるのか？

魚のワクチンは持続可能な水産養殖の基礎として登場し、養殖魚の集団における感染症を制御するための予防的かつ科学的に高度な方法を提供しています。水産養殖が世界の水産物需要の供給において天然捕獲漁業を凌駕し続ける中、疾病の発生は生産性、収益性、バイオセキュリティーに対する最も重大な脅威の一つとなっています。ワクチン接種は、抗菌剤耐性（AMR）と闘い、食品生産における化学物質の使用を削減するための世界のイニシアティブに合致し、抗生物質に代わる環境に配慮した選択肢を提供します。魚のワクチンは、Aeromonas salmonicida、Vibrio anguillarum、伝染性膵壊死ウイルス（IPNV）などの細菌、ウイルス、寄生虫性病原体に対して一般的に展開されています。これらの病気は、管理されなければ、高い死亡率、魚の健康状態の悪化、深刻な経済的損失につながる可能性があります。政府や業界の利害関係者は、特にサケ、ティラピア、シーバス、トラウトなどの高価値魚種において、標準的なベストプラクティスとしてワクチン接種を義務付けたり、奨励したりするようになってきています。その結果、魚のワクチンは集約的養殖においてもはやオプションとはみなされなくなり、群れの免疫力、生産効率、世界な水産物のサプライチェーンの安定性を維持するために不可欠なものとなっています。

技術の進歩はどのように魚のワクチンの範囲と有効性を広げているのでしょうか？

ワクチン製剤、送達、診断支援における技術革新は、魚のワクチンの有効性と利用しやすさを大幅に向上させています。従来の不活化ワクチンや弱毒化ワクチンは、現在、より高い特異性、より長い免疫期間、副作用リスクの低減を提供する組換えワクチン、サブユニットワクチン、DNAワクチンによって補完されています。カプセル化技術やアジュバント技術は、課題の多い水生環境においても、ワクチンの取り込みや免疫原性を向上させています。経口および浸漬ベースの送達方法における革新は、特に小型魚や幼魚において、従来の注射ベースのアプローチと比較して、ワクチン接種をより実用的で、魚の個体群にとってストレスの少ないものにしています。同時に、リアルタイムの水質モニタリングや疾病サーベイランスシステムなどの精密養殖ツールにより、的を絞ったワクチン接種スケジュールと、より優れた発生予防が可能になっています。ゲノミクスや分子診断学の利用も、新たな病原体の特定や、種特異的ワクチンの開発を加速させるのに役立っています。自動化されたワクチン投与システムは、特に大量の養殖場において、労働効率を改善し、一貫した投与を可能にしています。これらの技術的進歩は、魚類ワクチン接種プログラムの拡張性を向上させるだけでなく、手作業やインフラが限られている発展途上の水産養殖部門において、より広範な採用を可能にしています。

市場拡大において、規制、バイオセキュリティの要求、業界の協力はどのような役割を果たすのか？

規制による支援と業界の協調的努力は、魚のワクチン市場の世界的拡大において中心的役割を果たしています。ノルウェー、チリ、スコットランド、カナダなど水産養殖業が先進的な国々では、政府の政策や獣医当局が国の魚類衛生管理の枠組みの一部としてワクチンの使用を積極的に推進しています。ワクチン接種は、認証、輸出承認、無病地帯プログラムへの参加に必要とされることが多いです。抗生物質や化学薬品の使用を制限するバイオセキュリティー規制は、疾病緩和戦略の中核としてワクチンの採用をさらに強化しています。アジア太平洋、アフリカ、ラテンアメリカの新興市場では、官民パートナーシップとドナー資金による養殖開発プログラムが、ワクチン接種を大規模に実施するために必要なインフラとトレーニングの構築を支援しています。また、地域の水産養殖協会や研究開発機関は、製薬会社と協力し、熱帯・亜熱帯気候における特定の病原体の課題に対応する、地域特有のワクチン株を開発しています。さらに、水産養殖管理協議会（ASC）が提供するようなトレーサビリティと持続可能性の認証は、ワクチンを健康管理計画に組み込んでいる養殖場への報奨を増やし、市場参入と消費者の信頼を高めています。このような協力的で規制的な力学は、経済的インセンティブ、公衆衛生目標、そして責任ある養殖業への共通のコミットメントと業界の成長を一致させつつあります。

魚のワクチンの世界的需要急増の原動力は？

世界の魚のワクチン市場の成長は、水産養殖生産量の増加、疾病圧力の激化、規制の変化、持続可能性の要請の組み合わせによってもたらされています。特に中国、インド、インドネシア、ベトナムのような国々では、養殖が食料安全保障と農村の生活の中心となっています。生産が集約的になるにつれて、養殖場内および養殖場間での疾病感染のリスクは高まり、包括的なワクチン接種戦略が必要となります。抗生物質不使用の水産物を求める消費者需要の高まりも、特に北米で、市場参入の要件として生産者にワクチン導入を促しています。技術革新は、費用対効果の高いワクチン生産、多病原性製剤、ロジスティクスの改善を可能にし、中小規模の生産者でも魚のワクチンを実行可能にしています。一方、気候変動と環境悪化は病原体の動態を変化させ、ストレスによる疾病発生の頻度を高めており、予防的な魚類衛生ソリューションの必要性をさらに浮き彫りにしています。動物衛生企業、養殖バイオテクノロジー企業、および政府機関による継続的な投資は、ワクチン研究、菌株ライブラリー、および世界の流通ネットワークを加速させています。生物学的必要性、市場需要、規制政策、環境スチュワードシップにまたがるこれらの成長促進要因は、世界の魚のワクチン市場を、持続可能な水産養殖の将来にとって急速な拡大と戦略的重要性の段階へと総体的に押し上げています。

セグメント

ワクチンタイプ（キルドワクチン、不活化ワクチン、急性化ワクチン、トキソイドワクチン、サブユニットワクチン、混合ワクチン、遺伝子組換えベクターワクチン）、適応症（せつ腫症、ビブリオーシス、エルシニー症、腸性敗血症、その他の適応症）、投与経路（注射、浸漬、スプレー、経口）

調査対象企業の例（全44件）

• AquaTactics Fish Health
• Benchmark Holdings plc
• CAVAC
• Ceva Sante Animale
• Chengdu Tech-bank Biological Products
• Elanco Animal Health Inc.
• HIPRA
• Indian Immunologicals Ltd.
• KBNP Inc.
• Kemin Industries
• Kyoritsuseiyaku Corporation
• Kyoto Biken Laboratories, Inc.
• Merck Animal Health
• Nisseiken Co., Ltd.
• Phibro Animal Health Corporation
• Tecnovax
• Vaxxinova International BV
• Veterquimica S.A.
• Virbac
• Zoetis Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しており、当社の新リリースは地理的市場への関税の影響を組み込んでいます。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Fish Vaccines Market to Reach US$577.5 Million by 2030

The global market for Fish Vaccines estimated at US$363.9 Million in the year 2024, is expected to reach US$577.5 Million by 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Killed Vaccine, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$183.0 Million by the end of the analysis period. Growth in the Inactivated Vaccine segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$99.1 Million While China is Forecast to Grow at 12.9% CAGR

The Fish Vaccines market in the U.S. is estimated at US$99.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$126.5 Million by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.

Global Fish Vaccines Market - Key Trends & Drivers Summarized

Why Are Fish Vaccines Becoming Critical to Sustainable Aquaculture Growth?

Fish vaccines have emerged as a cornerstone of sustainable aquaculture practices, offering a proactive and scientifically advanced method for controlling infectious diseases in farmed fish populations. As aquaculture continues to outpace wild-capture fisheries in supplying global seafood demand, disease outbreaks have become one of the most significant threats to productivity, profitability, and biosecurity. Vaccination provides an environmentally responsible alternative to antibiotics, aligning with global initiatives to combat antimicrobial resistance (AMR) and reduce chemical use in food production. Fish vaccines are commonly deployed against bacterial, viral, and parasitic pathogens such as Aeromonas salmonicida, Vibrio anguillarum, and infectious pancreatic necrosis virus (IPNV), among others. These diseases, if unmanaged, can lead to high mortality rates, compromised fish health, and severe economic losses. Governments and industry stakeholders are increasingly mandating or incentivizing vaccination as a standard best practice, particularly in high-value species like salmon, tilapia, seabass, and trout. As a result, fish vaccines are no longer considered optional in intensive aquaculture-they are now essential for maintaining herd immunity, production efficiency, and global seafood supply chain stability.

How Are Technological Advancements Expanding the Reach and Efficacy of Fish Vaccines?

Technological innovations in vaccine formulation, delivery, and diagnostic support are significantly enhancing the effectiveness and accessibility of fish vaccines. Traditional inactivated and live-attenuated vaccines are now being supplemented by recombinant, subunit, and DNA vaccines that offer greater specificity, longer immunity, and reduced risk of side effects. Encapsulation and adjuvant technologies are improving vaccine uptake and immunogenicity, even in challenging aquatic environments. Innovations in oral and immersion-based delivery methods are making vaccination more practical and less stressful for fish populations compared to conventional injection-based approaches, particularly in small or juvenile fish. At the same time, precision farming tools-such as real-time water quality monitoring and disease surveillance systems-are enabling targeted vaccination schedules and better outbreak prevention. The use of genomics and molecular diagnostics is also helping identify emerging pathogens and develop species-specific vaccines at a faster rate. Automated vaccine administration systems, particularly in high-volume fish farms, are improving labor efficiency and ensuring consistent dosing. These technological advancements are not only improving the scalability of fish vaccination programs but are also enabling broader adoption in developing aquaculture sectors where manual labor and infrastructure are limited.

What Role Do Regulations, Biosecurity Demands, and Industry Collaboration Play in Market Expansion?

Regulatory support and coordinated industry efforts are playing a central role in scaling up the fish vaccines market globally. In countries with advanced aquaculture industries-such as Norway, Chile, Scotland, and Canada-government policies and veterinary authorities actively promote vaccine use as part of national fish health management frameworks. Vaccination is often required for certification, export approval, and participation in disease-free zone programs. Biosecurity regulations that restrict the use of antibiotics and chemicals are further reinforcing the adoption of vaccines as a core disease mitigation strategy. In emerging markets across Asia-Pacific, Africa, and Latin America, public-private partnerships and donor-funded aquaculture development programs are helping build the infrastructure and training needed to implement vaccination at scale. Regional aquaculture associations and research institutions are also collaborating with pharmaceutical companies to develop localized vaccine strains that address specific pathogen challenges in tropical and subtropical climates. Additionally, traceability and sustainability certifications-such as those offered by the Aquaculture Stewardship Council (ASC)-increasingly reward farms that integrate vaccines into health management plans, boosting market access and consumer trust. These collaborative and regulatory dynamics are aligning economic incentives, public health objectives, and industry growth with a shared commitment to responsible aquaculture.

What’s Driving the Global Surge in Demand for Fish Vaccines?

The growth in the global fish vaccines market is driven by a combination of rising aquaculture output, intensifying disease pressures, regulatory shifts, and sustainability imperatives. A key driver is the ongoing expansion of aquaculture as a primary protein source, particularly in countries like China, India, Indonesia, and Vietnam, where fish farming is central to food security and rural livelihoods. As production becomes more intensive, the risk of disease transmission within and between farms escalates, necessitating comprehensive vaccination strategies. Increasing consumer demand for antibiotic-free seafood-particularly in Europe and North America-is also pushing producers to adopt vaccines as a market-access requirement. Technological innovations are enabling cost-effective vaccine production, multi-pathogen formulations, and improved logistics, making fish vaccines viable even for small- and medium-scale producers. Meanwhile, climate change and environmental degradation are altering pathogen dynamics and increasing the frequency of stress-induced disease outbreaks, further highlighting the need for preventative fish health solutions. Continued investment from animal health companies, aquaculture biotech firms, and government agencies is accelerating vaccine research, strain libraries, and global distribution networks. These growth drivers-spanning biological necessity, market demand, regulatory policy, and environmental stewardship-are collectively powering the global fish vaccines market into a phase of rapid expansion and strategic importance for the future of sustainable aquaculture.

SCOPE OF STUDY:

The report analyzes the Fish Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine, Recombinant Vector Vaccines); Indication (Furunculosis, Vibriosis, Yersiniosis, Enteric Septicemia, Other Indications); Administration Route (Injection, Immersion, Spray, Oral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AquaTactics Fish Health
• Benchmark Holdings plc
• CAVAC
• Ceva Sante Animale
• Chengdu Tech-bank Biological Products
• Elanco Animal Health Inc.
• HIPRA
• Indian Immunologicals Ltd.
• KBNP Inc.
• Kemin Industries
• Kyoritsuseiyaku Corporation
• Kyoto Biken Laboratories, Inc.
• Merck Animal Health
• Nisseiken Co., Ltd.
• Phibro Animal Health Corporation
• Tecnovax
• Vaxxinova International BV
• Veterquimica S.A.
• Virbac
• Zoetis Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Fish Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Disease Prevention in Aquaculture Propels Growth in the Fish Vaccines Market
  • Expansion of Commercial Fish Farming Operations Expands the Addressable Market for Preventive Veterinary Vaccines
  • Increased Incidence of Bacterial, Viral, and Parasitic Outbreaks Throws the Spotlight on Fish Health Management
  • Regulatory Push for Antibiotic-Free Aquaculture Strengthens the Business Case for Vaccination-Based Disease Control
  • Technological Advancements in Oral, Immersion, and DNA Vaccines Drive Innovation in Fish Immunization Methods
  • Growth in Global Seafood Consumption Supports Long-Term Investment in Sustainable Fish Health Solutions
  • Rising Awareness of Economic Losses Due to Fish Mortality and Morbidity Spurs Demand for Effective Vaccines
  • Integration of Fish Vaccines in Hatchery Management and Early Life Stage Programs Improves Survival Rates and ROI
  • Emerging Zoonotic and Cross-Species Pathogen Risks Throw the Spotlight on Proactive Aquatic Disease Prevention
  • Customization of Vaccines for Species-Specific and Region-Specific Pathogens Enhances Market Precision and Impact
  • Growth in Recirculating Aquaculture Systems (RAS) Drives Need for Controlled, Preventive Fish Health Strategies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Fish Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Fish Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Killed Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Killed Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Killed Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Toxoid Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Toxoid Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Conjugate Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Conjugate Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Recombinant Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Recombinant Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Recombinant Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Yersiniosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Yersiniosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Yersiniosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Enteric Septicemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Enteric Septicemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Enteric Septicemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Furunculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Furunculosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Furunculosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Vibriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Vibriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Vibriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Immersion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Immersion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Immersion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Spray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Spray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Spray by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• JAPAN
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• CHINA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• EUROPE
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Fish Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• FRANCE
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• GERMANY
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 128: UK Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Spain 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Russia 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Fish Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Australia 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• INDIA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 185: India Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: India 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: South Korea 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Fish Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Latin America 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Argentina 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Brazil 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Mexico 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Fish Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Fish Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Middle East 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Iran 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Israel 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: UAE 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030
• AFRICA
  • Fish Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Fish Vaccines by Vaccine Type - Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Fish Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Killed Vaccine, Inactivated Vaccine, Attenuated Vaccine, Toxoid Vaccine, Subunit Vaccine, Conjugate Vaccine and Recombinant Vector Vaccines for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Fish Vaccines by Indication - Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Fish Vaccines by Indication - Percentage Breakdown of Value Sales for Yersiniosis, Enteric Septicemia, Other Indications, Furunculosis and Vibriosis for the Years 2015, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Fish Vaccines by Administration Route - Injection, Immersion, Spray and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Africa 15-Year Perspective for Fish Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injection, Immersion, Spray and Oral for the Years 2015, 2025 & 2030

IV. COMPETITION